NEW YORK (

TheStreet

) -- Popular searches on the Internet include

Deutsche Telekom

(DT) - Get Report

after

AT&T

(T) - Get Report

dropped its $39 billion bid for the Germany company's

T-Mobile USA

unit.

Deutsche Telekom told investors Tuesday it was working on a long-term plan for the wireless unit, though it offered no details on how it plans to move on from the deal's fallout. The company has secured a $6 billion break-up package, including about $3 billion in cash. AT&T will also give T-Mobile a package of wireless frequencies in 128 markets, as well as a seven-year roaming deal that will increase T-Mobile's potential customer coverage.

Deutsche Telekom had planned to turn its focus to growth in Europe amid the ongoing debt crisis after unloading T-Mobile. Now some speculate that

Sprint Nextel

(S) - Get Report

, which reportedly previously had been interested in a deal with T-Mobile, could still be a potential buyer.

Lockheed Martin

(LMT) - Get Report

is trending as the company beat out competitors for a contract with Japan for F-35 Joint Strike Fighter jets.

Japan will buy 42 of the aircraft, valued at over $7 billion. The country had also considered the

Boeing

(BA) - Get Report

F-18 or the Eurofighter Typhoon for its next-generation fighter jets but is said to have been attracted to the F-35's stealth capabilities.

AstraZeneca

(AZN) - Get Report

is another popular topic. The drugmaker will take a $381.5 million pretax charge in the fourth quarter after two of the drugs in its pipeline performed poorly in late-stage clinical trials.

AstraZeneca said its cancer drug olaparib will not progress into final Phase III testing, while antidepressant TC-5214 failed to reach its goal for its second Phase III study. Despite the charges, the company maintains it still expects to meet its expectations for 2011, with earnings per share now at the low end of its forecast.

Remaining studies for TC-5214 should be completed in the first half of 2012, after which AstraZeneca said it will review its plans for the drug. It is still possible that the drug will be submitted in the U.S. for approval in the second half of 2012.

The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar

.

Brittany joined TheStreet.com TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.